SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Auric Goldfinger's Short List -- Ignore unavailable to you. Want to Upgrade?


To: pilapir who wrote (10029)6/12/2002 11:02:00 AM
From: StockDung  Respond to of 19428
 
Former ImClone CEO Arrested

By DEVLIN BARRETT
.c The Associated Press

NEW YORK (AP) - The former CEO of ImClone Systems was arrested Wednesday and charged with conspiracy to commit securities fraud for allegedly tipping off two people to sell stock in the biotech company the day before federal regulators rejected its application for a cancer drug.

FBI agents arrested Samuel Waksal at his home at 6:30 a.m., said Waksal's spokesman, Scott Tagliarino. Waksal was replaced as ImClone CEO by his brother, Harlan, on May 22.

According to the complaint unsealed Wednesday, Waksal is accused of tipping off an unidentified person in Florida to sell 50,000 shares of ImClone stock on Dec. 27. He is also charged with allegedly tipping off a second person that same day who later sold nearly 40,000 shares.

Waksal is also charged with perjury for allegedly lying to the Securities and Exchange Commission about conversations he had with the people who received the tips.

The company's stock has plummeted by 90 percent since December because of the Food and Drug Administration's rejection of its application for the cancer drug Erbitux and because of the investigations into possible insider trading.

Before the rejection was announced Dec. 28, four of Samuel Waksal's relatives sold a total of $400,000 in company stock. Additionally, one of Sam Waksal's daughters reportedly reaped $2.5 million from selling shares. His friend Martha Stewart, the domestic lifestyle businesswoman, also shed 3,000 shares.

Stewart's spokesman had said she received no inside information on ImClone.

A congressional subcommittee is looking at ImClone and whether the FDA's secretive approval process for new drugs makes it easier to manipulate stocks.


06/12/02 10:47 EDT



To: pilapir who wrote (10029)6/12/2002 11:27:16 AM
From: StockDung  Respond to of 19428
 
.National Bank's P.I. serviced scores besides Weiss

2002-06-12 08:09 PT - Street Wire

by Brent Mudry

Most-wanted American financial fugitive Shalom Weiss, a notorious offshore client that Pacific International Securities denies servicing, was a major player in an OTC Bulletin Board promotion which featured numerous accounts at the controversial Vancouver brokerage. Pro Net Link Corp., now bankrupt, was under active investigation by the United States Securities and Exchange Commission in mid-1998, during a period when Pacific International was the brokerage of choice for Mr. Weiss and at least five other major company insiders.

Shalom Weiss, 47, also known as Sholam Weiss, appeared in U.S. District Court for the Middle District of Florida in Orlando on Tuesday, his first public appearance since he vanished on Oct. 18, 1999, the day before jury deliberations after a nine-month federal trial which resulted in a record 845-year sentence. He was a key player in the $450-million mortgage and real estate fraud of National Heritage Life Insurance Co., which was the biggest-ever criminal insurance fraud in U.S. history. (All figures are in U.S. dollars.) Mr. Weiss was extradited from Vienna, on Sunday, where he was tracked down and arrested on Oct. 24, 2000, after a year-long global manhunt featuring police in Israel, Brazil, Belgium, Germany, Hungary and Austria.

Mr. Weiss, once a respected member of New York's Hasidic Jewish community, shuffled into court wearing a bright-red jail jumpsuit, regulation thongs and matching leg shackles. While Mr. Weiss might get five years knocked off his massive sentence, as one of his dozens of charges, obstruction of justice, is not recognized under Austria's extradition treaty, he faces a new setback, according to Orlando Sentinel reporter Susan Clary.

The Department of Justice, stepping up to the plate for some hardball, is trying to yank Mr. Weiss's Miami extradition counsel, Sam Burstyn, because he defended another National Heritage convict, Isaak Rosenberg, who is married to one of Mr. Weiss's cousins. According to the Sentinel's Ms. Clary, Mr. Burstyn claims his fine client Mr. Weiss was illegally kidnapped and whisked out of Austria on a government jet Sunday, two weeks after he feigned a heart attack to dodge being shipped home on a scheduled commercial jet. "The only disease he has is prisonitis -- extreme fear of federal prison," retired FBI Special Agent Joe Judge told the newspaper.

Meanwhile, Stockwatch has uncovered more details of Mr. Weiss's dealings at Pacific International, a Vancouver brokerage charged last July by the British Columbia Securities Commission for servicing more than its share of stock crooks, securities violators and other dubious clients. In addition to vigorously defending the serious, but as-yet-unproven BCSC charges, Pacific International has denied Stockwatch's documented evidence, largely obtained through BCSC searches, that it ever serviced big-league racketeer and money launderer Mr. Weiss.

"Mr. Weiss is not and never has been a client of Pacific International," stated Vancouver lawyer Brian Baynham of Harper Grey Easton in a legal warning letter to Stockwatch in January. "This story and earlier stories of a similar vein have the potential of doing irreparable harm to my client's good name and reputation," he stated. Stockwatch has broken dozens of articles, dating back to early 1999, chronicling Pacific International's misfortune at being named as a stock or money laundering conduit in numerous U.S. indictments, criminal complaints and SEC prosecutions, duly noting the brokerage was never named as a target itself until the BCSC launched its prosecution a year ago.

While the public records of the BCSC's probe show Pacific International allegedly serviced Mr. Weiss through several offshore accounts, including Amex Corp., based in Geneva, and Dagon Developments, based in Israel, no details of stock trading have yet been revealed.

To help fill in the blanks for Mr. Baynham, he might be quite interested to look at Pro Net Link. The name of his client, Pacific International, is peppered in the National Association of Securities Dealers' list of Form 144 filings by company insiders who were keen to dump their holdings of Pro Net, or at least lighten their loads. Of the six brokerages noted, Pacific International is not only the sole Canadian house, but the busiest firm, with 26 entries, dwarfing runner-up Brown Brothers Harriman, with just eight.

Even more impressive is the breadth of Pacific International's client list. The Vancouver-based brokerage had accounts for no less than 22 separate clients, dominated by offshore and other European accounts. Oddly enough, none of the names of the Vancouver brokerage's clients are recognizable Vancouver, or even Canadian, penny stock players.

The first entry, dated May 29, 1998, is for a chap called Fode Diop, who filed to sell 110,000 shares. The busy Mr. Diop also filed to sell 20,000 shares on Sept. 3, 1998, 200,000 shares three weeks later, on Sept. 29, and a hefty 500,000 shares on Jan. 12, 1999. All four times Mr. Diop showed Pacific International Securities as his brokerage. While Mr. Diop's home address is not clear, someone using his name used a postbox address in Senegal in an unrelated penny stock promotion a year earlier. While Senegal might not seem like a major hotbed of international finance, Mr. Diop is doing his part to change this, serving as vice-president of the country's junior chamber of economics, which is like the junior chamber of commerce.

Next in line on the 144 list is Amex Corp., the offshore account the BCSC asserts is directly linked to or controlled by Mr. Weiss, despite lawyer Mr. Baynham's vigorous assertions. Amex Corp. filed to sell 200,000 shares of Pro Net Link on Aug. 26, 1998.

This was a particularly busy day, as two other Pacific International clients filed to sell a total of almost 600,000 shares. A company called Firstimpex filed to sell 385,000 shares, while Judith Lerner filed to sell 200,000 shares. Five days later, on Aug. 31, 1998, a fifth Pacific International client, Charles Neisenbaum, filed to sell 80,000 Pro Net shares.

The same day, a new brokerage appeared on the list: Millennium Securities Corp., whose client Nicole Peignier filed to sell 500,000 shares. Millennium showed up once more on the list, on July 15, 1999, when client Muriel Prochasson wanted to dump 500,000 Pro Net shares.

Millennium, based in New York, had the misfortune of being shut down by regulators a year ago. The NASD launched a prosecution on April 13, 2000, claiming the brokerage, its chief executive officer Richard Sitomer and its president Todd Rome made $5-million in illegal profits rigging the initial public offering of another penny promo, Translation Group, in December, 1996. The firm was expelled by the NASD on June 15, 2001, and clients face an Aug. 12 deadline to file claims with SIPC, the Securities Investor Protection Corp.

Besides servicing the most Pro Net insiders, Pacific International also serviced the biggest: a client called Pioneer Info Systems, which filed to sell 1.5 million shares on March 15, 1999. Pioneer Info also filed to sell 50,000 shares on July 7, 1999, again through Pacific International.

In addition to Mr. Diop, Mr. Weiss's Amex Corp., Firstimpex, Ms. Lerner, Mr. Niesenbaum and Pioneer Info, Pacific International also serviced numerous other Pro Net insiders who made 144 filings up to Sept. 30, 1999, including Usines Diffusion, Jean Scarpaci, Jean Emilio Mula, Bernard Zoller, Oliver Texier, Serge Touitou, Claude Delas, Andre Martinez, Gerald Testaniere, Roger Daveaux and Gilles Marret.

All this may seem to be much ado about nothing, but for two details. The first relates to the SEC, while the second relates to Mr. Weiss.

"In June, 1998, the Securities and Exchange Commission commenced an investigation of Pro Net Link relating primarily to the alleged manipulation of the market for securities of Pro Net Link, pursuant to a formal order issued by the SEC under the authority of Sections 20(a) and 21(a) of the Securities Exchange Act of 1934, as amended," states the company in a regulatory filing. "Pursuant to that formal order, subpoenas for the production of books, papers, documents and other records were served on Pro Net Link and on companies doing business with us. Testimony was required of Mr. Collardeau and Mr. Zagoren (Pro Net's top executives.)"

"Pro Net Link, Mr. Collardeau and Mr. Zagoren complied with the subpoenas and all related requests of the SEC in June and July 1998, and have received no further inquiries from the SEC regarding this investigation. We have no information as to the results, if any, of such investigation, whom the targets, if any, of such investigation were or may be, or what action, if any, the SEC may take pursuant to the investigation," states the company. Pro Net filed for bankruptcy last June, the same month Millennium was shut down for good.

Even more intriguing is Firstimpex, the Pacific International client which filed to sell 385,000 Pro Net shares on Aug. 26, 1998, the same day Mr. Weiss's Amex filed to sell 200,000 shares through the Vancouver brokerage.

In what can only be described as an amazing coincidence, Firstimpex also showed up as a major shareholder of Saf T Lok Inc. As Stockwatch has reported earlier, Pacific International serviced both mortgage fraudster Mr. Weiss, a key player in the fraudulent 1997 bulletin board promotion of Saf T Lok, and controversial fraudbuster, Anthony Elgindy, who exposed and shorted the promotion. (There is no suggestion Mr. Elgindy and Mr. Weiss were acting in concert or even knew each other.)

One of Mr. Weiss's chief Saf T Lok fronts was a friend, Arthur Braun, the president of United Safety Action Inc., a Saf T Lok distributor, and the owner of A. B. & Associates, a shell consultant related to Mr. Weiss's Regulation S offshore private placement.

In yet another tidbit of penny stock trivia, Mr. Elgindy is credited with exposing legendary Internet stock tout fraudster Tokyo Joe, who frequented Scores, the upscale New York Gambino family strip club which featured National Heritage as a major owner and Mr. Weiss as both a key backer and a regular patron.



To: pilapir who wrote (10029)6/12/2002 11:54:56 AM
From: StockDung  Read Replies (1) | Respond to of 19428
 
SECURITIES AND EXCHANGE COMMISSION V. SAMUEL D. WAKSAL

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
LITIGATION RELEASE NO. 17559 / June 12, 2002

SECURITIES AND EXCHANGE COMMISSION V. SAMUEL D. WAKSAL

02-CIV-4407 (NB) (S.D.N.Y.)

On June 12, 2002, the Securities and Exchange Commission filed charges against the former CEO of ImClone Systems Inc. (IMCL), Samuel Waksal, for illegal insider trading. The Commission filed its complaint in the United States District Court for the Southern District of New York. In its complaint, the Commission charges that: (1) in late December 2001, Waksal received disappointing news about ImClone: the United States Food and Drug Administration (FDA) would soon issue a decision rejecting for review ImClone's pending application to market its cancer treatment, Erbitux; (2) Waksal told this negative information to certain family members who sold ImClone stock before the news became public; and (3) Waksal himself tried to sell shares of ImClone before the news became public.

The Commission's complaint alleges that based on this conduct, Waksal violated Section 17(a) of the Securities Act of 1933 and Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder.

Specifically, the Commission's complaint alleges as follows.

On the evening of December 26, 2001, Waksal learned that on December 28, 2001, the FDA would issue a Refusal to File (RTF) letter to ImClone rejecting consideration of its Biologics Licensing Application for Erbitux.

The same evening and early the next morning, Waksal called certain family members to alert them that ImClone would be receiving this bad news.

As soon as the market opened the next morning, December 27, these family members sold more than $9 million of ImClone stock. In total they sold more than $10 million of ImClone stock over the next two days.

Also starting that evening, December 26, and through December 28, Waksal himself tried to sell 79,797 shares of ImClone stock worth nearly $5 million. He was unable to do so only because two different broker-dealers would not execute the orders.

As expected, the FDA faxed ImClone the RTF letter at about 4 p.m. on December 28, 2001. At 6 p.m. that day, ImClone publicly announced the FDA decision. By the close of trading on December 31, the next trading day, ImClone's stock price had dropped 16%, from $55.25 to $46.46.

By selling before the announcement that ImClone had received an RTF letter from the FDA, Waksal family members avoided losses of several million dollars.
In its lawsuit, the Commission seeks an order requiring that Waksal disgorge the losses avoided by those family members he tipped, and that he pay civil penalties and prejudgment interest. It also seeks an order permanently enjoining Waksal from violating the securities laws, and barring him from acting as an officer or director of a public company.

The Commission's investigation is ongoing. The Commission acknowledges the assistance of the United States Attorney's Office for the Southern District of New York in the investigation of this matter.

sec.gov

--------------------------------------------------------------------------------



To: pilapir who wrote (10029)6/12/2002 12:00:52 PM
From: StockDung  Respond to of 19428
 
Martha Stewart shares fall on ex-ImClone CEO arrest

NEW YORK, June 12 (Reuters) - Shares of Martha Stewart Living Omnimedia Inc. <MSO.N> fell sharply on Wednesday on concerns about Martha Stewart's personal involvement with the the former head of ImClone Systems Inc., who was arrested on insider trading charges, analysts said.

Stewart, the home design and decorating diva, sold about 3,000 shares of ImClone <IMCL.O> shortly before the company's experimental cancer drug was rejected by the Food and Drug Administration.

ImClone's former chief executive, Sam Waksal, was arrested on Wednesday and charged with conspiracy, securities fraud and perjury involving an alleged insider trading scheme in ImClone shares.

Stewart, a former girlfriend of Waksal, has denied any wrongdoing in the matter and, through a company spokesman, has said she was not acting on nonpublic information when she sold her ImClone shares. The company spokesman was not immediately available to comment on Wednesday.

Nevertheless, Wall Street analysts said Stewart's proximity to the insider trading case has shaken investors, pressuring the stock to its lowest level since mid-January. Since her stock sales were first reported late last week, Martha Stewart shares have fallen nearly 21 percent.

In heavy trading this morning, the stock was down $2, or nearly 12 percent, to $15.10, and was among the biggest percentage losers on the New York Stock Exchange.

The stock was falling on "concerns related to Martha Stewart's dealings with ImClone," said George Smith, an analyst at Davenport & Co.

"Shares of the company fell last week when the news of the trades came out," said Brean Murray & Co. analyst Kathleen Heaney. "There's no reason they wouldn't also fall when (Waksal) was arrested."

The importance of Martha Stewart and her image to her company cannot be overstated, analysts said. Any link to a criminal proceeding could have lingering effects.

"If this becomes an issue that spreads beyond Barrons and the Wall Street Journal to People, Time Magazine and Saturday Night Live, that could have a real impact (on the company)," Davenport's Smith said.
06/12/02 11:33 ET



To: pilapir who wrote (10029)6/12/2002 12:21:25 PM
From: StockDung  Read Replies (1) | Respond to of 19428
 
Knight Trading Loses 14% After It Is Sued by Shareholders

By TSC Staff

06/11/2002 05:38 PM EDT

Knight Trading (NITE:NYSE - news - commentary - research - analysis) fell 14% Tuesday after word emerged that it had been sued by shareholders for allegedly inflating its profits.

The complaint filed in federal court in Newark, N.J., charges that Knight lied about the company's trading practices, revenues and earnings, causing its share price to inflate. While the language is boilerplate for shareholder suits filed after a company delivers bad news, the suit is evidently the first to be filed after Knight acknowledged that it was the subject of an investigation by securities regulators. The NASD and SEC are probing allegations Knight traders ripped off clients by "front-running," or trading ahead of orders to profit on expected price changes.


The suit filed by the Los Angeles law firm of Glancy & Binkow LLP seeks to represent shareholders who bought Knight stock between Feb. 29, 2000, and June 3, 2002.

Knight has confirmed the investigation but said the allegations are false and have been lodged by a former employee who was fired. A representative wasn't immediately available to comment on the shareholder suit.

Knight's shares fell 76 cents, or 14%, to $4.74 Tuesday, one day after the lawsuit was made public.



To: pilapir who wrote (10029)6/12/2002 8:41:08 PM
From: StockDung  Respond to of 19428
 
Couple Sues MTV Over Hidden-Camera 'Corpse' Prank

By Steve Gorman

LOS ANGELES (Reuters) - MTV has been slapped with a $10 million lawsuit from a couple who say they were surprised by a fake corpse in their hotel room as part of a hidden-camera prank for a reality TV show.

James and Laurie Ann Ryan, of Washington, D.C., also named the Hard Rock Hotel in Las Vegas in the suit, which accuses the resort and the cable network of invasion of privacy, infliction of emotional distress and fraud, among other things, their attorney said on Wednesday.

The suit, originally filed in Los Angeles in April but gaining public attention this week after it was moved to federal court, said the couple became unwitting participants in a practical joke filmed for a series under development at MTV called "Harassment" while they were on vacation in January.

Upon entering the hotel room, the Ryans "discovered what appeared to be a dead human body covered and surrounded by blood, evidently the victim of a homicide," as hidden cameras recorded their shock, the suit says.

As the couple tried to flee, two actors posing as security guards blocked their way, and a third individual in the guise of a paramedic entered the room.

The show's host and co-producer, Ashton Kutcher, who has described the series in interviews as a "guerrilla-style Candid Camera," finally emerged to reveal the prank.

The Ryans were not amused. They are seeking $10 million in compensatory damages against MTV, the Hard Rock Hotel and Kutcher, who also is named in the suit, said their lawyer, Daniel Rozansky.

Both the cable network, which is owned by Viacom Inc., and the privately owned hotel declined to comment on the case.

An MTV spokeswoman said the incident in question was filmed as part of a pilot episode for "Harassment," which has not aired. She said the future status of the program is uncertain.

"Harassment" is not the first reality show to land MTV in legal trouble. Two teenage girls sued the network in April, 2001 after they were sprayed with human excrement by performers billed as the "Shower Rangers" during the taping of a program called "Dude, This Sucks."

MTV apologized for the incident and promised never to air footage of the incident. That suit remains in litigation, the girls' high-profile Los Angeles attorney Gloria Allred told Reuters.


06/12/02 20:11 ET



To: pilapir who wrote (10029)6/12/2002 8:43:50 PM
From: StockDung  Respond to of 19428
 
Ex-ImClone CEO Indicted for Fraud

By DEVLIN BARRETT
.c The Associated Press

NEW YORK (AP) - The former chief executive of ImClone Systems was indicted on insider trading charges Wednesday for what prosecutors say was a flurry of late-night and early morning phone calls to relatives who quickly cashed out their shares before the company's stock price plummeted.

Samuel Waksal, 54, allegedly tried to save himself and his family from staggering losses last December when he learned the FDA was about to reject his company's application for approval of a highly touted cancer drug.

A criminal complaint unsealed Wednesday in Manhattan federal court charges that Waksal helped two unidentified people sell millions of dollars in ImClone stock just before the FDA decision was made public.

A source familiar with the investigation told The Associated Press on condition of anonymity that Waksal is accused of warning his father and one of his daughters about the government's decision on the drug Erbitux.

Court papers show five quick calls between Waksal and ``Tippee 1'' - identified by the source as his father. The calls began just before 10 p.m. on Dec. 26 and the last call came at 11:11 p.m.

The next day at 6:30 a.m., Waksal called ``Tippee 2,'' identified by the source as his daughter Aliza, as she vacationed in Sun Valley, Idaho, and the two spoke five more times before 8 a.m., according to court papers.

``Tippee 1'' quickly sold $6.7 million worth of ImClone stock on Dec. 27th, the day before the Erbitux announcement; ``Tippee 2'' sold $2.5 million in shares, according to court documents.

According to a civil lawsuit filed by the SEC, Waksal relatives sold more than $10 million in ImClone stock within a 48-hour period.

Between Dec. 26 and Dec. 28, the stock price dropped from $63.62 to $55.25. Selling 100,000 shares at the higher price, for example, would save more than $800,000.

Waksal was arrested about 6:30 a.m. Wednesday at his Tribeca home. He was charged with conspiracy to commit securities fraud and perjury for allegedly lying to the SEC about his phone conversations. If convicted, he faces up to 10 years on the fraud charge and up to five years each on the other three counts.

Waksal's lawyer Mark Pomerantz called the prosecution's evidence ``entirely circumstantial. The government misread that evidence and it overreacted in deciding to make today's arrest,'' he said.

U.S. Attorney James Comey would not say if any of Waksal's relatives could still be charged.

``He was charged with conspiracy, so obviously we'll look at the full scope of that conduct and examine anybody whose conduct falls within that fraction of the universe,'' Comey said.

At a court appearance Wednesday afternoon, U.S. Magistrate Judge Frank Maas released Waksal on $10 million bond, on the condition that he put up half of that amount in cash by Friday. As part of the bail package, Waksal will not be allowed to leave the New York area, and his brother Harlan, now the CEO of ImClone, will co-sign the bond.

Long before Waksal was arrested, he stood out in the traditionally staid pharmaceutical and biotech industries. The reed-thin scientist was known for holding celebrity-studded salons and glitzy parties in his downtown apartment. The June issue of Vanity Fair listed Mick Jagger, Mort Zuckerman, Martha Stewart and Andrew Cuomo among the guests at his Christmas party.

Stewart shed her remaining stake of 3,000 shares on Dec. 27. Stewart's spokesman have said she received no inside information on ImClone.

``I did not speak to Dr. Samuel Waksal regarding my sale, and did not have any nonpublic information regarding ImClone when I sold my ImClone shares,'' Stewart said in a statement issued Wednesday. ``After directing my broker to sell, I placed a call to Dr. Waksal's office to inquire about ImClone. I did not reach Dr. Waksal and he did not return my call.

``In placing my trade I had no improper information. My transaction was entirely lawful.''

ImClone's fortunes are totally dependent on Erbitux, an experimental cancer drug that initially garnered the company widespread praise and enthusiastic investors who drove up the stock price. The shares have plummeted by 90 percent since December because of the FDA's decision and because of the investigations into possible insider trading.

Shares in ImClone were lower most of Wednesday but ended the day higher, gaining 28 cents to $7.83 each on the Nasdaq Stock Market.

In addition to the criminal charges, the SEC filed a civil lawsuit Wednesday charging that Waksal tried to sell 79,797 of his own shares worth nearly $5 million before the information became public.

Officials said Waksal was unable to do so because two brokerage firms wouldn't execute his sell order because there were restrictions on the trading he could do of his own company's shares.

Court papers also offer an $80 million motive for Waksal's alleged behavior. According to the criminal complaint, he was carrying more than $80 million in debt at the time of the Erbitux announcement, and had to make monthly payments of $800,000 to service the debt.

The SEC now wants Waksal to pay back ``several million dollars'' in losses it says were avoided by the family members he tipped, and also is seeking an order barring him from serving as an officer or director of any publicly traded company.

A subcommittee of the House Committee on Energy and Commerce is looking at ImClone and whether the FDA's secretive approval process for new drugs makes it easier to manipulate stocks.

Ken Johnson, a spokesman for the committee, said that based on the federal complaint, it appears that Sam Waksal lied to congressional investigators.

The court granted a Justice Department motion to amend the conditions of Sam Waksal's bail to allow him to testify in Washington on Thursday, Johnson said.

``We fully expect Mr. Waksal to appear before our committee tomorrow or we will seek contempt of Congress charges,'' he said.

Pomerantz said he expected Waksal would be there.

The subcommittee widened its probe Wednesday to include Harlan Waksal. ``We have serious questions about what he knew, when he knew it and did it affect his decision to sell nearly $50 million of ImClone stock,'' Johnson said.

He said the probe refers to a Dec. 5 stock sale, which came a day after FDA officials first indicated to the company that there was a problem with its drug application.


06/12/02 20:05 EDT